Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.64 Analyst target: $12.00 Upside: 1777.05%
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company is headquartered in EmeryVille, California.
See the full interactive analysis & chart →Informational only — not investment advice.